Academic Editor: Brian Tomlinson
The role of lipocalin 2 (LCN2) in pulmonary hypertension (PH) in pediatric
patients with congenital heart disease (CHD) remains unclear. We sought to
investigate whether LCN2 could be a potential biomarker for PH in pediatric
patients who underwent surgery for CHD. From December 2018 to February 2020,
patients undergoing surgical repair for congenital defects with and without PH
were identified. Healthy children without CHD and PH served as controls. A mean
pulmonary artery pressure (mPAP)